Okay, here’s a breakdown of the key information from the provided text, focusing on the concerns surrounding Høeg’s appointment and the potential changes at the FDA:
1. The Core Issue: Potential Shift in FDA Direction
* Changes to Vaccine Schedule: The FDA is considering changes to the U.S. childhood vaccine schedule, perhaps aligning it with Denmark’s (which has fewer routinely administered vaccines). This proclamation has been delayed until the new year.
* Concerns about Regulation: There’s growing worry about a potential weakening of drug regulations except for vaccines, which may face increased scrutiny and potential restriction.
* Consolidation of Power: Some believe Høeg’s appointment, along with Vinay Prasad’s role, represents a power consolidation by individuals skeptical of vaccines within the FDA.
2. Why Høeg’s Appointment is Controversial
* Lack of Customary Qualifications: Høeg lacks the typical background for a CDER (Center for Drug Evaluation and Research) director – no experience in drug development, regulation, or management, or leading large organizations. She hasn’t run clinical trials or worked in industry regulation.
* Previous Advocacy: She has consistently advocated for a more restrained approach to childhood vaccinations, specifically referencing the Danish model.
* Questionable Research:
* She used unconfirmed crowd-sourced reports to assess heart inflammation after COVID vaccination.
* She advised Florida’s surgeon general, who allegedly altered data related to COVID vaccine safety.
* She previously expressed a desire to revise vaccine regulations and eliminate “needless” vaccines.
* Proposed Exclusion of Young Men from COVID vaccines: She reportedly proposed excluding young men from receiving COVID vaccines.
* Characterization as an “Ideologue”: Critics accuse her of starting with conclusions and then manipulating evidence to support them.
3. Context & Related Concerns
* Danish model: The proposed changes are based on Denmark’s vaccination practices, raising questions about the applicability of that model to the U.S. healthcare system.
* Priority Voucher Program: Høeg’s arrival coincides with a controversial fast-track drug approval program, raising concerns about openness and selection criteria.
* Appointments of Similar Figures: Høeg joins other publicly critical figures of the COVID pandemic handling (Makary, Bhattacharya) in prominent positions.
* HHS Defense: The Department of Health and Human services defends the appointment, stating Høeg’s background aligns with the role, citing her work on drug safety and regulatory science.
In essence,the article paints a picture of a potential shift in the FDA’s approach to drug and vaccine regulation,driven by appointments of individuals with unconventional backgrounds and a history of questioning established practices. This is raising concerns about the agency’s independence, transparency, and commitment to evidence-based decision-making.
